|
MaxCyte Inc and Ori Biotech Ltd on Wednesday announced a collaboration aimed at boosting efficiency and scalability in cell and gene therapy manufacturing. The two firms have integrated MaxCyte’s Expert platform and Ori’s IRO system to improve the yield of gene-edited T cells and shorten manufacturing timelines. The partnership focuses on enhancing production processes for autologous cell therapies, using CD19 CAR expression via CRISPR knock-in in activated T cells as a test case. MaxCyte, a Rockville, Maryland-based cell engineering technology company, said its Flow Electroporation technology, which is already used in over 19 clinical and commercial programs, will be paired with Ori’s automated fluid handling and sterile connection system to streamline post-electroporation cell expansion. ‘This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients,’ said MaxCyte Chief Executive Officer Maher Masoud. Ori Biotech CEO Jason Foster added that the partnership reflects a shared aim to bring therapies to patients ‘faster, more reliably, and at greater scale’ by using modular, best-of-breed technologies. Shares in MaxCyte were down 2.7% at 167.40 pence in London on Wednesday afternoon. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
